Myriad Genetics reports interim MONSTAR-SCREEN-3 data showing Precise MRD test prognostic value across cancers at ASCO 2026

Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN

0.00
  • Myriad Genetics will present new clinical data on its Precise MRD blood test at the 2026 ASCO Annual Meeting.
  • Interim findings from the MONSTAR-SCREEN-3 study indicate the assay can detect residual disease signals across multiple solid tumors.
  • Patients with post-surgery ctDNA positivity showed poorer disease-free survival, supporting the test’s use to flag higher recurrence risk.
  • The readout strengthens Myriad’s push to broaden adoption of tumor-informed MRD monitoring to guide treatment and surveillance decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270905PRIMZONEFULLFEED9726936) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.